Novo Nordisk acquires Dicerna for USD 3.3bn

Novo Nordisk is acquiring the US-based biotech business Dicerna for USD 3.3bn. The two companies are already collaborating within NASH, type 2 diabetes and obesity, in addition to rare diseases.

BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

On Thursday, Novo Nordisk announces in a press release that it is acquiring the US-based firm Dicerna, which has been a frequent collaborator of the Danish pharmaceutical company since 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo Nordisk has picked second RNA drug candidate for USD 358m collaboration
For subscribers
Novo Nordisk within touching distance of European obesity market as CHMP recommends approval
For subscribers
Novo increases fatty liver efforts: "We've seen some highly convincing data"
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

"We're not just talking about an alternative to GLP. We actually believe the data is so strong that we have reason to believe that petrelintide could become the backbone of obesity treatment if we succeed," says CEO Adam Steensberg. | Foto: Stine Bidstrup

Pharma & biotech

Zealand Pharma sitting pretty after "probably one of Europe's strongest capital raises ever"

The development of the obesity drug petrelintide must be accelerated now, says CEO Adam Steensberg.

Zealand sells USD 1 billion in shares to fund new obesity drugs

Zealand Pharma is very open to partnership after promising obesity data

For subscribers

Pharma & biotech

Bavarian Nordic submits chikungunya vaccine for approval in Europe

For subscribers

Novo Nordisk does not have enough capacity to meet the demand for its products. | Foto: Gregers Tycho

Pharma & biotech

Media: Novo Nordisk in talks to buy factory

For subscribers

Foto: M. Spencer Green/AP/Ritzau Scanpix

Pharma & biotech

Innovent and Eli Lilly release weight loss candidate data, plan to compete with Novo in China

Adam Steensberg, CEO, Zealand Pharma | Foto: Stine Bidstrup

Pharma & biotech

Zealand sells USD 1 billion in shares to fund new obesity drugs

For subscribers

Pharma & biotech

Novo Nordisk CEO to testify before senate committee in September

For subscribers

Novo Nordisk sets new record as market value surpasses USD 650bn
Each share in Novo Nordisk now costs over USD 145.
UK court gives NHS green light to claim damages against Lundbeck
Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.
For subscribers
Pfizer is testing three new weight loss candidates
Two of the experimental drugs are GLP-1 agents.
For subscribers
Teva to launch generic copy of Novo Nordisk drug in the US
Sales of type 2 diabetes drug Victoza dropped last year.
FDA accepts Lundbeck's application for Rexulti as supplementary PTSD treatment
Lundbeck and partner Otsuka submitted the application in April, and now the FDA will review it for possible approval.
Eli Lilly appoints Nordic Head of Public Affairs
He comes from a position as government affairs director in the Nordics for Vertex Pharmaceuticals and has previously also worked for Novo Nordisk.
For subscribers

Pfizer is testing three new weight loss candidates

Two of the experimental drugs are GLP-1 agents.

For subscribers

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.

For subscribers